Epidemiología de las fracturas en el Servicio de Urgencias del Hospital Central Militar

Contenido principal del artículo

Luis Roberto García Valadez
Saúl Israel Guzmán Espinosa
Edgardo Montelongo Mercado

Resumen

No existe una estadística precisa de los padecimientos ortopédicos traumáticos atendidos en el Servicio de Urgencias del Hospital Central Militar.

Detalles del artículo

Sección

Artículos de investigación

Cómo citar

1.
Epidemiología de las fracturas en el Servicio de Urgencias del Hospital Central Militar. RSM [Internet]. 2025 Apr. 10 [cited 2025 Oct. 29];67(4). Available from: https://revistasanidadmilitar.org/index.php/rsm/article/view/2549

Referencias

Edman RL, Wolfe JT. Prevention and Early Detection of Malignant Melanoma, Philadelphia, Pennsylvania Am Fam Physician 2000; 62(10): 2277-85.

Jemal A, Siegel R, Xu J, Ward E. Cancer Statistics. Ca Cancer J Clin 2010; 60: 277-300.

Flaherty AEL. El tratamiento del melanoma maligno. Curr Treat Oncol Opciones; 6(3): 185-93.

Dom W, Schuchter LM. El Melanoma Maligno. University of Pensilnania Cancer Center. Division de Hematologia. Oncologia 16 Penn Tower, 3400 Spruce Street, Philadelphia PA 19104-4283, EE.UU

Robinson JK, Turrisi R. Skills Training to Learn Discrimination of ABCDE Criteria by Those at Risk of Developing Melanoma. Arch Dermatol 2006; 142.

Gogas HJ, Kirkwood JM, Sondak VK. Chemotherapy for Metastatic MelanomaTime for a Change? Cancer 2007;109: 455-64.

Nasser N. Cutaneous melanoma A 30-year-retrospective epidemiological study conducted in a city in southern Brazil, from 1980- 2009. An Bras Dermatol 2011; 86(5): 932-41.

Minor DR. Clinical Trial of Sutent to Treat Metastatic Melanoma, California Pacific Medical Center, September 14, 2009, Contact: Ron Frianeza 415-600-3027

Livingstone E, Zimmer L, Vaubel J, Schadendorf D. Current advances and perspectives in the treatment of advanced melanoma, Journal der Deutschen Dermatologischen Gesellschaft 2012; 10(5): 319-25.

Fauci AS, Kasper DL, Braunwald E, Hauser SL, Longo DL, Jameson JL, Loscalzo J. Harrisons Principles of Internal Medicine, 17/a edicion: http://accesmedicine.com/, Cancer of the skin, Cap, 83.

'Crosby T, Fish R, Coles B, Mason M. Systemic treatments for metastatic cutaneous melanoma. Cochrane Database of Systematic Reviews 2000, Issue 2. Art. No.: CD001215. DOI: 10.1002/14651858.CD001215

Sladden MJ, Balch C, Barzilai DA, Berg D, Freiman A, Handiside T, Hollis S, et al. Surgical excision margins for primary cutaneous melanoma. Cochrane Database of Systematic Reviews 2000.

Silva JH, de Sa' BC, Avila ALR, Landman G, DupratNeto JP. Atypical mole syndrome and dysplastic nevi: identification of populations at risk fordeveloping melanoma review article. Clinics 2011; 66(3): 493-9.

Cornejo KM, Deng AC. Malignant melanoma within squamous cell carcinomaand basal cell carcinoma: is it a combined or collisiontumor? A Case Report and Review of the Literature. Am J Dermatopathol 2012.

Kerl K, Palmedo G, Wiesner Y, Mentzel T, Rütten A, Scharer L, Paredes B. A Proposal for Improving Multicolor FISH Sensitivity in the Diagnosis of Malignant Melanoma Using New Combined Criteria. Am J Dermatopathol 2012; 34(16): 580-5.

Atkins MB, Lotze MT, Dutcher JP, Fisher RI, Weiss G, Margolin K, Abrams J, et al. Rosenberg, High-Dose Recombinant Interleukin 2 Therapy for PatientsWith Metastatic Melanoma: Analysis of 270 Patients Treated Between 1985 and 1993. J Clin Oncol 1999; 17(7): 2105-116.

Ahmadzadeh M, Antony PA, Steven A. IL-2 and IL-15 Each Mediate De Novo Induction of FOXP3Expression in Human Tumor Antigen-specific CD8 T Cells Rosenberg Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, J Immunother 2007; 30(3): 294-302.

Carlos-Ortega B, Montes de Oca-Monroy F. Impacto de la dermatoscopia en la práctica clínica. Rev Med Inst Mex Seguro Soc 2009; 47(6): 581-2.

Carlos-Ortega B, Montes de Oca-Monroy F, Isyta-Morales A. Dermatoscopia de las metástasis de melanoma maligno cutáneo. Informe de caso. Rev Med Inst Mex Seguro Soc 2009; 47(1): 73-6.

MDX-010 Antibody, MDX-1379 Melanoma Vaccine, or MDX-010/MDX-1379 Combination Treatment for Patients With Unresectable or Metastatic Melanoma, ClinicalTrials.gov identifier: NCT00094653, Bristol-Myers Squibb.

Glanz K, Yaroch AL, Dancel M, Saraiya M, Crane LA, Buller DB, Manne S, et al. Measures of Sun Exposure and Sun Protection Practices for Behavioral and Epidemiologic Research. Arch Dermatol 2008; 144(2).

Mundth ED, Guralnick EA, Raker JJW. Malignant Melanoma: A Clinical Study of 427 Cases. Annals of Surgery 1965; 162(1).

Artículos similares

También puede Iniciar una búsqueda de similitud avanzada para este artículo.

Artículos más leídos del mismo autor/a